Beta
Trial Radar KI
enums.trial_summary.trial_summary_welcome
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes (EXPET)

Offene Rekrutierung
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT04754581 (EXPET) ist eine interventionsstudie zur Untersuchung von Typ-2-Diabetes und hat den Status offene rekrutierung. Die Studie startete am 30. März 2021 und soll 12 Teilnehmer aufnehmen. Durchgeführt von AdventHealth Translational Research Institute ist der Abschluss für 1. Juni 2025 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 27. September 2024 aktualisiert.
Kurzbeschreibung
The overall aim of this pilot study is to investigate the effects of exercise training on skeletal muscle and adipose tissue insulin resistance in subjects with Type 2 Diabetes (T2D).
Offizieller Titel

Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes

Erkrankungen
Typ-2-Diabetes
Weitere Studien-IDs
  • EXPET
  • 1581803
NCT-Nummer
NCT04754581
Studienbeginn (tatsächlich)
2021-03-30
Zuletzt aktualisiert
2024-09-27
Studienende (vorauss.)
2025-06
Geplante Rekrutierung
12
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Offene Rekrutierung
Primäres Ziel
Andere
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
AndereAll Participants
Maximal ATP Production (ATPMAX)
ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.
Exercise Testing (VO2MAX)
Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.
Muskelbiopsie
Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.
Fettgewebebiopsie
Sample fat tissue from the abdomen.
Hyperinsulinemic Euglycemic Clamp
Measurement of insulin sensitivity.
PET-Bildgebung
After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Individual steps of muscle glucose uptake (pre-exercise)
Muscle glucose uptake will be assessed two times (pre and post exercise intervention) on the biceps femoris and vastus lateralis through PET imaging and hyperinsulinemic euglycemic clamp.
24 hours
Individual steps of muscle glucose uptake (post-exercise)
Muscle glucose uptake will be assessed two times (pre and post exercise intervention) on the biceps femoris and vastus lateralis through PET imaging and hyperinsulinemic euglycemic clamp.
24 hours
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
30 Years
Zugelassene Geschlechter
Alle
Akzeptiert gesunde Freiwillige
Ja
  1. Age 30-65 years
  2. Men and women
  3. Body mass index (BMI) between 25 and 45 kg/m2
  4. Sedentary (1 day or less per week of structured exercise)
  5. Type 2 diabetes mellitus determined by self-report or by a fasting glucose >126mg/dl
  6. Weight stable (± 2 kg) for prior 3 months
  7. Willing to commit to the schedule of assessment visits, including the exercise intervention

  1. Currently taking insulin, injectable incretin mimetics and thiazolidinediones
  2. Taking more than two glucose-lowering medications
  3. Resting blood pressure ≥ 160/100 mm Hg
  4. Triglycerides ≥ 500 mg/dL
  5. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise training protocol
  6. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)
  7. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise training
  8. Pulse check ("Allen test") indicates participant has poor blood flow in the hands
  9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)
  10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year
  11. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc
  12. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures
  13. Participant is currently taking anti-inflammatory medication or has had inflammatory medication within 1 week prior to screening (including over the counter formulations: e.g. Aleve, Motrin, Ibuprofen, Naproxen, low dose ASA.
  14. New onset (<3 months on a stable regime) hormone replacement therapy
  15. Current use of beta-adrenergic blocking agents
  16. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
  17. Increased liver function tests (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal)
  18. Abnormal blood count/anemia, blood transfusion or blood donation within the last 2 months
  19. Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products)
  20. Current drug or alcohol abuse/dependence
  21. Metal implants (pace-maker, aneurysm clips) based on investigator's judgment at screening
  22. Not physically capable of performing the exercise required of the study protocols
  23. Plans to be away >2 weeks in the next 3 months
  24. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening.
  25. Unable to tolerate MRI or claustrophobia.
  26. Nickel allergy
  27. Lidocaine allergy
  28. Unable or unwilling to communicate with staff or to provide written informed consent
AdventHealth Translational Research Institute logoAdventHealth Translational Research Institute
Zentrale Studienkontakte
Kontakt: Recruitment Department, 407-303-7100, [email protected]
1 Studienstandorte in 1 Ländern

Florida

AdventHealth Translational Research Institute, Orlando, Florida, 32804, United States
Recruitment Department, Kontakt, 407-303-7100, [email protected]
Offene Rekrutierung